Pfizer and BioNTech's Coronavirus Vaccine Approved in Canada
On Tuesday, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) won another crucial approval from a major healthcare regulator for their coronavirus vaccine. Health Canada authorized the two companies' BNT162b2 for widespread and general use, writing that it meets the "stringent safety, efficacy and quality requirements for use in Canada."
Pfizer and BioNTech have an agreement to supply the country's health authorities with at least 20 million doses of the vaccine -- and up to 76 million if necessary -- through 2021. The inoculation protocol calls for individuals to receive two doses, 21 days apart. The initial indication of BNT162b2 is for use in people who are at least 16 years old. The companies said that they are prepared to begin deliveries as soon as the Canadian government is ready to receive them.
Image source: Getty Images.
Source Fool.com
